Info

ZYCOS Inc. is a privately held drug development company focused on developing antiviral and oncology products. Since its inception in 1996, the Company has generated a series of distinct new medical entities (NMEs) and with these conducted multiple clinical trials in chronic viral diseases and cancer. By exploiting an integrated suite of proprietary drug formulation technologies, the Company has consistently demonstrated the ability to accelerate product development, via formulation optimization with resulting clinical success. In partnering its lead drugs to experienced pharmaceutical companies, ZYCOS believes it can maximize it's value through efficient launch, marketing and distribution of its' products. In order to capture a larger fraction of the value it has created, ZYCOS will retain commercialization rights to drugs developed for specific indications in which large marketing efforts are not critical.